Steven Idell

US Patent:

20030219386, Nov 27, 2003

Filed:

Apr 4, 2003

Appl. No.:

10/407821

Inventors:

Steven Idell - Tyler TX, US

Assignee:

Board of Regents, The University of Texas System

International Classification:

A61L009/04
A61K038/46

US Classification:

424/045000, 424/094650

Abstract:

The present invention relates to methods of preventing or decreasing the severity of scarring in a subject comprising: obtaining a pharmaceutical composition comprising a single chain urokinase plasminogen activator molecule (scuPA) or a scuPA mimetic; and administering the pharmaceutical composition to a subject; wherein scarring in the subject is either prevented or decreased relative to an amount of scarring that would be expected if the pharmaceutical composition were not administered to the subject. The invention also relates to methods of screening for compounds that prevent or decrease the severity of scarring in a subject.

US Patent:

20040033200, Feb 19, 2004

Filed:

Oct 30, 2002

Appl. No.:

10/283482

Inventors:

Mirella Ezban - Kobenhavn K, DK
Claude Piantadosi - Durham NC, US
Steven Idell - Tyler TX, US

International Classification:

A61K038/39
A61L009/04

US Classification:

424/045000, 514/012000

Abstract:

The present invention relates to the use of modified factor VI[ for manufacture of medicaments for treatment of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS) in humans.

US Patent:

20050048045, Mar 3, 2005

Filed:

Jul 2, 2004

Appl. No.:

10/884195

Inventors:

Sreerama Shetty - Tyler TX, US
Steven Idell - Tyler TX, US

International Classification:

A61K038/48

US Classification:

424094500

Abstract:

The present invention provides methods for treating inflammatory diseases, neoplastic diseases, wound healing and preventing scarring by administering a therapeutically effective amount of phosphoglycerate phosphokinase (PGK) peptide, polypeptide, protein, mutant or mimetic to a subject. The invention also relates to methods of screening for compounds for modulation of uPAR expression or activity. The present invention further provides coding sequences of phosphoglycerate kinase peptides, polypeptides, or proteins, or mutants, or mimetics thereof as a gene therapy for inflammatory diseases, cancer, wound healing, or tissue scarring.

US Patent:

20090227515, Sep 10, 2009

Filed:

Mar 5, 2009

Appl. No.:

12/398757

Inventors:

Sreerama Shetty - Tyler TX, US
Steven Idell - Tyler TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 38/00
C07K 7/00
A61K 38/10

US Classification:

514 13, 530326, 530300, 514 2

Abstract:

During lung injury, p53 expression increases, inducing plasminogen activator inhibitor-1 (PAI-1) while inhibiting expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), resulting in apoptosis of lung epithelial cells (LECs). In the bleomycin lung injury model, p53 and PAI-1 are induced while uPA and uPAR are inhibited. A 20 residue peptide DGIWKASFTTFTVTKYWFYR termed PP-1 (the Cav-1 scaffolding domain) or peptide NYHYLESSMTALYTLGH, termed PP-2, protected LECs from bleomycin-induced apoptosis in vitro and in vivo and prevented subsequent pulmonary fibrosis by attenuating lung epitheilial damage. Pharmaceutical compositions, peptide multimers and deliverable polypeptides comprising the above peptides are dislcosed. The peptides and functional variants, peptide multimers, cell-targeted polyepeptides and pharmaceutical compositions are used in methods for inhibiting apoptosis of injured or damaged lung epithelial cells and for treating acute lung injury and consequent pulmonary fibrosis.

US Patent:

20230100467, Mar 30, 2023

Filed:

Dec 2, 2022

Appl. No.:

18/061084

Inventors:

- Austin TX, US
Steven IDELL - Tyler TX, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

C07K 7/06
A61K 38/08
C07K 7/08
A61K 38/17
A61K 31/497
A61K 47/64
A61K 9/00

Abstract:

In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, as they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.

US Patent:

20210330741, Oct 28, 2021

Filed:

Jul 5, 2021

Appl. No.:

17/367532

Inventors:

- Austin TX, US
Steven IDELL - Tyler TX, US
Sreerama SHETTY - Tyler TX, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

A61K 38/17
A61K 38/49
A61K 9/00
A61K 9/19
A61K 38/10
A61K 38/08
A61K 9/14

Abstract:

Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI).

US Patent:

20210212988, Jul 15, 2021

Filed:

May 16, 2019

Appl. No.:

17/056238

Inventors:

- Fort Worth TX, US
Steven IDELL - Tyler TX, US

International Classification:

A61K 31/407
A61K 9/00
A61P 11/00

Abstract:

Pharmaceutical compositions and methods are described which rely upon glycogen synthase kinase 3 (form β; GSK 3β) inhibitors, most preferably 9-ING-41, to inhibit fibrotic pulmonary remodeling in vivo including proliferation and differentiation of myofibroblasts to fibrotic fibroblasts in several mouse models. Therapeutic targeting of GSK-3β with the clinically useful specific inhibitor, 9-ING-41, mitigates fibrotic pulmonary remodeling in vivo and provides a mode of therapy of human IPF by specific GSK-3β inhibition with 9-ING-41.

US Patent:

20200164028, May 28, 2020

Filed:

Nov 27, 2019

Appl. No.:

16/698452

Inventors:

- Austin TX, US
Steven IDELL - Tyler TX, US
Sreerama SHETTY - Tyler TX, US

International Classification:

A61K 38/17
A61K 9/14
A61K 9/19
A61K 9/00
A61K 38/49
A61K 38/08
A61K 38/10

Abstract:

Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI).